Subscribe to this collection to receive daily e-mail notification of new additions

Issue Date	Title	Type	Author(s)
2003	NUP98 is fused to adducin 3 in a patient with T-cell acute lymphoblastic leukemia and myeloid markers, with a new translocation t(10;11)(q25;p15)	Articulo	Lahortiga, I. (Idoya); Vizmanos-Pérez, J.L. (José Luis); Agirre-Ena, X. (Xabier), et al
2003	Lack of Bcr-Abl point mutations in chronic myeloid leukemia patients in chronic phase before imatinib treatment is not predictive of response	Articulo	Agirre-Ena, X. (Xabier); Fontalba, A. (A.); Andreu, E.J. (Enrique José), et al
2004	Chromosomal abnormalities clustering in multiple myeloma reveals cytogenetic subgroups with nonrandom acquisition of chromosomal changes	Articulo	Saez, B. (Borja); Martin-Subero, J.I. (Jose Ignacio); Guillen-Grima, F. (Francisco), et al
2005	Coexistence of different clonal populations harboring the b3a2 (p210) and e1a2 (p190) BCR-ABL1 fusion transcripts in chronic myelogenous leukemia resistant to imatinib	Articulo	Agirre-Ena, X. (Xabier); Roman-Gomez, J. (José); Vazquez, I. (Iria), et al
2007	Simultaneous translocations of FGFR3/MMSET and CCND1 into two different IGH alleles in multiple myeloma: lack of concurrent activation of both proto-oncogenes	Articulo	Saez, B. (Borja); Martin-Subero, J.I. (Jose Ignacio); Lahortiga, I. (Idoya), et al
2006	Interphase FISH for the detection of breakpoints in IG loci and chromosomal changes with adverse prognostic impact in multiple myeloma with normal karyotypes	Articulo	Saez, B. (Borja); Martin-Subero, J.I. (Jose Ignacio); Odero, M.D. (Maria Dolores), et al
2009	Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia.	Articulo	San-Jose, E. (Edurne); Agirre-Ena, X. (Xabier); Jimenez-Velasco, A. (A.), et al

Recent Submissions

NUP98 is fused to adducin 3 in a patient with T-cell acute lymphoblastic leukemia and myeloid markers, with a new translocation t(10;11)(q25;p15)

Lack of Bcr-Abl point mutations in chronic myeloid leukemia patients in chronic phase before imatinib treatment is not predictive of response

Chromosomal abnormalities clustering in multiple myeloma reveals cytogenetic subgroups with nonrandom acquisition of chromosomal changes

Coexistence of different clonal populations harboring the b3a2 (p210) and e1a2 (p190) BCR-ABL1 fusion transcripts in chronic myelogenous leukemia resistant to imatinib

Simultaneous translocations of FGFR3/MMSET and CCND1 into two different IGH alleles in multiple myeloma: lack of concurrent activation of both proto-oncogenes

Interphase FISH for the detection of breakpoints in IG loci and chromosomal changes with adverse prognostic impact in multiple myeloma with normal karyotypes

Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia.